Compare Ascendis Pharma A/S (ASND) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Raymond James Financial, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Raymond James Financial, Inc. trades at $168.12 (market cap $32.76B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | RJF | |
|---|---|---|
Market Cap | $17.74B | $32.76B |
Sector | Health | Financials |
52-Week High | $277.18 | $176.43 |
52-Week Low | $163.32 | $140.89 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Raymond James Financial (RJF) trades at $168.12, down 0.36% today, with a bullish technical signal and strong earnings momentum after beating estimates in three consecutive quarters. Revenue growth is robust, with 2025 revenue reaching $13.84B and net income of $2.14B, though profit margins have moderated slightly. Analyst consensus is positive with a $176.83 price target, and the company maintains a solid dividend, recently declaring $0.54 per share payable in July 2026.
The outlook for RJF is favorable, supported by earnings beats and strategic investments, but risks include rising expenses and market volatility. Upside potential exists if cost management improves and revenue growth sustains, aligning with analyst targets. Key risks are competitive pressures and economic sensitivity, yet institutional sentiment remains bullish with no sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
